Fulcrum Therapeutics and the FSHD Clinical Trial Research Network Announce Clinical Trial Readiness Study

Cambridge, Mass., May 21, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, and the FSHD Clinical Trial Research Network (CTRN) today announced the initiation of a clinical trial readiness study.

Read More

Fulcrum Therapeutics to Present at BioCentury’s Future Leaders in the Biotech Industry Conference

Cambridge, Mass., March 15, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at BioCentury’s Future Leaders Conference in New York, NY.

Read More

Fulcrum Therapeutics to Present at the 11th Annual Future of Genomic Medicine Conference

San Diego, Calif., March 2, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at the 11th Annual Future of Genomic Medicine Conference in San Diego, Calif.

Read More

Fulcrum Therapeutics to Present at the Annual Society for Neuroscience Meeting

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at the Society for Neuroscience Annual Meeting held from November 11-15 in Washington, D.C.

Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

Cambridge, Mass., Oct. 11, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop, held in Quebec, Canada from October 12-16, 2017. Read More. 

Fulcrum Therapeutics to Present at the 10th Annual BioPharm America International Partnering Conference

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at the 10th Annual BioPharm America International Partnering Conference in Boston, Mass.

Robert Gould, Ph.D., Fulcrum’s President and Chief Executive Officer, will give a presentation in the Rare and Orphan Disease category titled “Restoring Balance in Gene Regulation” at the Sheraton Boston Hotel on September 27th at 10:45am. Read More.

Fulcrum Therapeutics to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference, to be held September 8, 2017 in New York City.

Robert Gould, Ph.D., Fulcrum’s President and Chief Executive Officer, and Amit Hasija, Chief Business Officer, will give a presentation titled “Restoring Balance in Gene Regulation” at 11:30 a.m. at the Millennium Broadway Hotel & Conference Center.

 

Fulcrum Therapeutics Named Finalist for the 2017 Xconomy Awards in the Patient Partnership Category

Cambridge, Mass., August 9, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced that it has been named a finalist for the 2017 Xconomy Awards in the Patient Partnership category. Read More.